Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marcus Bauser

Showing results (11-20 of 26) with videos related to

Pageof 3
Sort By:
Chemmedchem|April 3, 2020
Computationally Empowered Workflow Identifies Novel Covalent Allosteric Binders for KRAS<sup>G12C</sup>Jérémie Mortier, Anders Friberg, Volker Badock, et al.
Journal of Medicinal Chemistry|May 22, 2013
Design, synthesis, and initial evaluation of a high affinity positron emission tomography probe for imaging matrix metalloproteinases 2 and 9Svetlana V Selivanova, Timo Stellfeld, Tobias K Heinrich, et al.
Molecular Cancer Therapeutics|August 18, 2018
Preclinical Efficacy of the Novel Monocarboxylate Transporter 1 Inhibitor BAY-8002 and Associated Markers of ResistanceMaria Quanz, Eckhard Bender, Charlotte Kopitz, et al.
Nuclear Medicine and Biology|May 24, 2014
Gene expression levels of matrix metalloproteinases in human atherosclerotic plaques and evaluation of radiolabeled inhibitors as imaging agents for plaque vulnerabilityAdrienne Müller, Stefanie D Krämer, Romana Meletta, et al.
ACS Combinatorial Science|August 13, 2016
Efficient Routes to a Diverse Array of Amino Alcohol-Derived Chiral FragmentsSina Haftchenary, Shawn D Nelson, Laura Furst, et al.
Leukemia|April 4, 2019
The novel dihydroorotate dehydrogenase (DHODH) inhibitor BAY 2402234 triggers differentiation and is effective in the treatment of myeloid malignanciesSven Christian, Claudia Merz, Laura Evans, et al.
Cellular Oncology (Dordrecht, Netherlands)|January 25, 2021
The potent AMPK inhibitor BAY-3827 shows strong efficacy in androgen-dependent prostate cancer modelsClara Lemos, Volker K Schulze, Simon J Baumgart, et al.
Journal of Medicinal Chemistry|April 28, 2023
Discovery of an Oral, Beyond-Rule-of-Five Mcl-1 Protein-Protein Interaction Modulator with the Potential of Treating Hematological MalignanciesFedor Romanov-Michailidis, Chien-Chi Hsiao, Lorenz M Urner, et al.
Journal of Medicinal Chemistry|February 28, 2018
Creation of a Novel Class of Potent and Selective MutT Homologue 1 (MTH1) Inhibitors Using Fragment-Based Screening and Structure-Based Drug DesignFredrik Rahm, Jenny Viklund, Lionel Trésaugues, et al.
Journal of Medicinal Chemistry|October 26, 2021
Discovery and Characterization of the Potent and Highly Selective 1,7-Naphthyridine-Based Inhibitors BAY-091 and BAY-297 of the Kinase PIP4K2ALars Wortmann, Nico Bräuer, Simon J Holton, et al.
Pageof 3

Showing results (11-20 of 26) with videos related to

Sort By:
Pageof 3
Chemmedchem|April 3, 2020
Computationally Empowered Workflow Identifies Novel Covalent Allosteric Binders for KRAS<sup>G12C</sup>Jérémie Mortier, Anders Friberg, Volker Badock, et al.
Journal of Medicinal Chemistry|May 22, 2013
Design, synthesis, and initial evaluation of a high affinity positron emission tomography probe for imaging matrix metalloproteinases 2 and 9Svetlana V Selivanova, Timo Stellfeld, Tobias K Heinrich, et al.
Molecular Cancer Therapeutics|August 18, 2018
Preclinical Efficacy of the Novel Monocarboxylate Transporter 1 Inhibitor BAY-8002 and Associated Markers of ResistanceMaria Quanz, Eckhard Bender, Charlotte Kopitz, et al.
Nuclear Medicine and Biology|May 24, 2014
Gene expression levels of matrix metalloproteinases in human atherosclerotic plaques and evaluation of radiolabeled inhibitors as imaging agents for plaque vulnerabilityAdrienne Müller, Stefanie D Krämer, Romana Meletta, et al.
ACS Combinatorial Science|August 13, 2016
Efficient Routes to a Diverse Array of Amino Alcohol-Derived Chiral FragmentsSina Haftchenary, Shawn D Nelson, Laura Furst, et al.
Leukemia|April 4, 2019
The novel dihydroorotate dehydrogenase (DHODH) inhibitor BAY 2402234 triggers differentiation and is effective in the treatment of myeloid malignanciesSven Christian, Claudia Merz, Laura Evans, et al.
Cellular Oncology (Dordrecht, Netherlands)|January 25, 2021
The potent AMPK inhibitor BAY-3827 shows strong efficacy in androgen-dependent prostate cancer modelsClara Lemos, Volker K Schulze, Simon J Baumgart, et al.
Journal of Medicinal Chemistry|April 28, 2023
Discovery of an Oral, Beyond-Rule-of-Five Mcl-1 Protein-Protein Interaction Modulator with the Potential of Treating Hematological MalignanciesFedor Romanov-Michailidis, Chien-Chi Hsiao, Lorenz M Urner, et al.
Journal of Medicinal Chemistry|February 28, 2018
Creation of a Novel Class of Potent and Selective MutT Homologue 1 (MTH1) Inhibitors Using Fragment-Based Screening and Structure-Based Drug DesignFredrik Rahm, Jenny Viklund, Lionel Trésaugues, et al.
Journal of Medicinal Chemistry|October 26, 2021
Discovery and Characterization of the Potent and Highly Selective 1,7-Naphthyridine-Based Inhibitors BAY-091 and BAY-297 of the Kinase PIP4K2ALars Wortmann, Nico Bräuer, Simon J Holton, et al.
Pageof 3